PaxMedica, Getty Images And 3 Short Squeeze Candidates That Could Soar This Week

Potential short squeeze plays gained steam in 2021 and have continued through 2022 with new traders looking for the next huge move.

High short interest and a high cost to borrow are among the common traits that could lead to a short squeeze. Here’s a look at the top five short squeeze candidates based on the Fintel short squeeze leaderboard.

PaxMedica Inc PXMD: The clinical stage biopharmaceutical company, which develops treatments for autism spectrum disorder, tops the short squeeze leaderboard for the week. Data shows 16.8% of the float short and a cost to borrow of 140.2%. The Tarrytown, New York-based company was on the leaderboard last month, which was only a couple months after its August 2022 IPO. PaxMedica was ranked 30th in the previous week’s leaderboard, marking the biggest move of the top five short squeeze candidates.

Related Link: What Is A Short Squeeze

Getty Images GETY: The content creator and image marketplace rejoins the leaderboard’s top five candidates after ranking 12th last week. The Seattle-based company, which went public via SPAC merger, previously topped the leaderboard in earlier November. Data shows 84.5% of the float short and a cost to borrow of 198.1%. Last week, the report showed 84.5% of the float short and a cost to borrow of 181.7%. Benzinga identified the stock as one to watch that could jump back into the top five candidates.

Hour Loop HOUR: The e-commerce company is the lone carryover from last week’s top five short squeeze candidates. The stock moves down two places after topping the list last week. Data shows 15.6% of the float short, in line with last week’s report. The cost to borrow of 56.8% is slightly higher than last week’s reported 55.5%.

SurgePays Inc SURG: The fintech company ranks fourth on the leaderboard moving up 14 places from last week. The company previously was a top five short squeeze candidate in October. Data shows 63.9% of the float short and a cost to borrow of 7.1%.

Abeona Therapeutics ABEO: Clinical stage biopharmaceutical company Abeona Therapeutics joins the leaderboard for the week, moving up 9 places from last week’s report. Data shows 5.6% of the float short and a cost to borrow of 17.5%.

Read Next: How To Short A Stock